This Monday, May 15th, representatives from bioXclusters plus and Fenglin Group signed a Gateway Agreement to offer free services and guidance for SMEs in their operations in China. Services will include assistance in market access, private investment, clinical trials and soft landing packages. Continue reading
There’s no question that China is an appealing market for the biotech industry. This is not only because of the possibilities it offers for lowering R&D costs, but also because of its market size. Demographics are a reason for this country’s attractiveness: a large and progressively wealthier population that is getting older represents a new market of potential users of biotech products.
But investing in China is not an easy process. The lack of transparency and the challenges related to regulatory issues make the process long and difficult, in addition to the maze of authorities involved. Continue reading